- $58.26m
- $54.37m
- $27.64m
Annual cashflow statement for ImmuCell, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 8-K |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.078 | -2.49 | -5.77 | -2.16 | — |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.194 | 0.295 | 0.495 | 0.234 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.62 | -1.83 | -2.11 | -0.407 | 2.48 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 0.954 | -1.54 | -4.67 | 0.358 | 2.48 |
| Capital Expenditures | -2.61 | -3.98 | -1.89 | -0.466 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.01 | 0.011 | 0.002 | 0.004 | -1.21 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.6 | -3.96 | -1.89 | -0.461 | -1.21 |
| Financing Cash Flow Items | 0.002 | -0.019 | -0.082 | -0.297 | -1.21 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.88 | 1.11 | 1.75 | 2.88 | -1.21 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.24 | -4.39 | -4.81 | 2.78 | 0.049 |